A citation-based method for searching scientific literature

Paolo Pozzilli, Emanuele Bosi, Deborah Cirkel, Julia Harris, Nicola Leech, Francisco J Tinahones, Marie-Christine Vantyghem, Georgios Vlasakakis, Anette-Gabriele Ziegler, Salim Janmohamed. J Clin Endocrinol Metab 2020
Times Cited: 5







List of co-cited articles
18 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Kevan C Herold, Brian N Bundy, S Alice Long, Jeffrey A Bluestone, Linda A DiMeglio, Matthew J Dufort, Stephen E Gitelman, Peter A Gottlieb, Jeffrey P Krischer, Peter S Linsley,[...]. N Engl J Med 2019
182
60

Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.
Nicklas J Johansen, Thomas F Dejgaard, Asger Lund, Camilla Schlüntz, Christian S Frandsen, Julie L Forman, Nicolai J Wewer Albrechtsen, Jens J Holst, Ulrik Pedersen-Bjergaard, Sten Madsbad,[...]. Lancet Diabetes Endocrinol 2020
11
40

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Bo Ahrén, Irl B Hirsch, Thomas R Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen,[...]. Diabetes Care 2016
71
40

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
Kevan C Herold, Stephen E Gitelman, Mario R Ehlers, Peter A Gottlieb, Carla J Greenbaum, William Hagopian, Karen D Boyle, Lynette Keyes-Elstein, Sudeepta Aggarwal, Deborah Phippard,[...]. Diabetes 2013
183
40

A combined risk score enhances prediction of type 1 diabetes among susceptible children.
Lauric A Ferrat, Kendra Vehik, Seth A Sharp, Åke Lernmark, Marian J Rewers, Jin-Xiong She, Anette-G Ziegler, Jorma Toppari, Beena Akolkar, Jeffrey P Krischer,[...]. Nat Med 2020
17
40

PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-α and-γ via IRF1 induction.
Maikel L Colli, Jessica L E Hill, Laura Marroquí, Jessica Chaffey, Reinaldo S Dos Santos, Pia Leete, Alexandra Coomans de Brachène, Flavia M M Paula, Anne Op de Beeck, Angela Castela,[...]. EBioMedicine 2018
61
40

The challenge of modulating β-cell autoimmunity in type 1 diabetes.
Mark A Atkinson, Bart O Roep, Amanda Posgai, Daniel C S Wheeler, Mark Peakman. Lancet Diabetes Endocrinol 2019
49
40

Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?).
Bart O Roep, Sofia Thomaidou, René van Tienhoven, Arnaud Zaldumbide. Nat Rev Endocrinol 2021
22
40

Verapamil and beta cell function in adults with recent-onset type 1 diabetes.
Fernando Ovalle, Tiffany Grimes, Guanlan Xu, Anish J Patel, Truman B Grayson, Lance A Thielen, Peng Li, Anath Shalev. Nat Med 2018
36
40

Expression of endoplasmic reticulum stress markers in the islets of patients with type 1 diabetes.
I Marhfour, X M Lopez, D Lefkaditis, I Salmon, F Allagnat, S J Richardson, N G Morgan, D L Eizirik. Diabetologia 2012
141
40

Insulitis and β-Cell Mass in the Natural History of Type 1 Diabetes.
Martha Campbell-Thompson, Ann Fu, John S Kaddis, Clive Wasserfall, Desmond A Schatz, Alberto Pugliese, Mark A Atkinson. Diabetes 2016
177
40

Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.
Manuela Battaglia, Simi Ahmed, Mark S Anderson, Mark A Atkinson, Dorothy Becker, Polly J Bingley, Emanuele Bosi, Todd M Brusko, Linda A DiMeglio, Carmella Evans-Molina,[...]. Diabetes Care 2020
70
40

Interferon-gamma drives programmed death-ligand 1 expression on islet β cells to limit T cell function during autoimmune diabetes.
Kevin C Osum, Adam L Burrack, Tijana Martinov, Nathanael L Sahli, Jason S Mitchell, Christopher G Tucker, Kristen E Pauken, Klearchos Papas, Balamurugan Appakalai, Justin A Spanier,[...]. Sci Rep 2018
39
40

Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients.
Ken T Coppieters, Francesco Dotta, Natalie Amirian, Peter D Campbell, Thomas W H Kay, Mark A Atkinson, Bart O Roep, Matthias G von Herrath. J Exp Med 2012
394
40

Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors.
Richard A Oram, Timothy J McDonald, Beverley M Shields, Michelle M Hudson, Maggie H Shepherd, Suzanne Hammersley, Ewan R Pearson, Andrew T Hattersley. Diabetes Care 2015
60
40

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
100
40

Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
Mark D Pescovitz, Carla J Greenbaum, Heidi Krause-Steinrauf, Dorothy J Becker, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Jennifer B Marks, Paula F McGee, Antoinette M Moran,[...]. N Engl J Med 2009
628
40

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.
Mark R Rigby, Kristina M Harris, Ashley Pinckney, Linda A DiMeglio, Marc S Rendell, Eric I Felner, Jean M Dostou, Stephen E Gitelman, Kurt J Griffin, Eva Tsalikian,[...]. J Clin Invest 2015
137
40

Glucagon-like peptide 1 in health and disease.
Andreas Andersen, Asger Lund, Filip K Knop, Tina Vilsbøll. Nat Rev Endocrinol 2018
124
20


Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.
Ronnie Aronson, Peter A Gottlieb, Jens S Christiansen, Thomas W Donner, Emanuele Bosi, Bruce W Bode, Paolo Pozzilli. Diabetes Care 2014
67
20

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Thomas Fremming Dejgaard, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Søren Urhammer, Ulrik Pedersen-Bjergaard, Tonny Jensen, Andreas Kryger Jensen, Jens Juul Holst, Lise Tarnow,[...]. Lancet Diabetes Endocrinol 2016
72
20

Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.
Nitesh D Kuhadiya, Sandeep Dhindsa, Husam Ghanim, Aditya Mehta, Antoine Makdissi, Manav Batra, Sartaj Sandhu, Jeanne Hejna, Kelly Green, Natalie Bellini,[...]. Diabetes Care 2016
43
20


Immune and Pancreatic β Cell Interactions in Type 1 Diabetes.
Joanne Boldison, F Susan Wong. Trends Endocrinol Metab 2016
28
20

Revisiting the role of inflammation in the loss of pancreatic β-cells in T1DM.
Decio L Eizirik, Maikel L Colli. Nat Rev Endocrinol 2020
3
33

Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL.
Reut Yosef, Noam Pilpel, Ronit Tokarsky-Amiel, Anat Biran, Yossi Ovadya, Snir Cohen, Ezra Vadai, Liat Dassa, Elisheva Shahar, Reba Condiotti,[...]. Nat Commun 2016
320
20

Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis.
Jay S Skyler, George L Bakris, Ezio Bonifacio, Tamara Darsow, Robert H Eckel, Leif Groop, Per-Henrik Groop, Yehuda Handelsman, Richard A Insel, Chantal Mathieu,[...]. Diabetes 2017
181
20

Mitochondrial Reactive Oxygen Species and Type 1 Diabetes.
Jing Chen, Scott E Stimpson, Gabriel A Fernandez-Bueno, Clayton E Mathews. Antioxid Redox Signal 2018
21
20

ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response.
Andrew N Blackford, Stephen P Jackson. Mol Cell 2017
575
20


Senescence is a developmental mechanism that contributes to embryonic growth and patterning.
Mekayla Storer, Alba Mas, Alexandre Robert-Moreno, Matteo Pecoraro, M Carmen Ortells, Valeria Di Giacomo, Reut Yosef, Noam Pilpel, Valery Krizhanovsky, James Sharpe,[...]. Cell 2013
525
20

Protection from autoimmune diabetes and T-cell lymphoproliferation induced by FasL mutation are differentially regulated and can be uncoupled pharmacologically.
Abdiaziz S Mohamood, Mehmet L Guler, Zuoxiang Xiao, Dongfeng Zheng, Allan Hess, Yi Wang, Hideo Yagita, Jonathan P Schneck, Abdel Rahim A Hamad. Am J Pathol 2007
20
20

Targeting senescent cells in translational medicine.
Marta Paez-Ribes, Estela González-Gualda, Gary J Doherty, Daniel Muñoz-Espín. EMBO Mol Med 2019
63
20

Perforin-independent beta-cell destruction by diabetogenic CD8(+) T lymphocytes in transgenic nonobese diabetic mice.
A Amrani, J Verdaguer, B Anderson, T Utsugi, S Bou, P Santamaria. J Clin Invest 1999
108
20

Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes.
Emily K Sims, Henry T Bahnson, Julius Nyalwidhe, Leena Haataja, Asa K Davis, Cate Speake, Linda A DiMeglio, Janice Blum, Margaret A Morris, Raghavendra G Mirmira,[...]. Diabetes Care 2019
42
20

Persistence of Pancreatic Insulin mRNA Expression and Proinsulin Protein in Type 1 Diabetes Pancreata.
Clive Wasserfall, Harry S Nick, Martha Campbell-Thompson, Dawn Beachy, Leena Haataja, Irina Kusmartseva, Amanda Posgai, Maria Beery, Christopher Rhodes, Ezio Bonifacio,[...]. Cell Metab 2017
45
20

Senolytics improve physical function and increase lifespan in old age.
Ming Xu, Tamar Pirtskhalava, Joshua N Farr, Bettina M Weigand, Allyson K Palmer, Megan M Weivoda, Christina L Inman, Mikolaj B Ogrodnik, Christine M Hachfeld, Daniel G Fraser,[...]. Nat Med 2018
504
20

Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice.
D Kägi, B Odermatt, P Seiler, R M Zinkernagel, T W Mak, H Hengartner. J Exp Med 1997
195
20

IRE1: ER stress sensor and cell fate executor.
Yani Chen, Federica Brandizzi. Trends Cell Biol 2013
277
20

Converting Adult Pancreatic Islet α Cells into β Cells by Targeting Both Dnmt1 and Arx.
Harini Chakravarthy, Xueying Gu, Martin Enge, Xiaoqing Dai, Yong Wang, Nicolas Damond, Carolina Downie, Kathy Liu, Jing Wang, Yuan Xing,[...]. Cell Metab 2017
94
20

The discovery of type 1 diabetes.
E A Gale. Diabetes 2001
73
20

Impact of islet architecture on β-cell heterogeneity, plasticity and function.
Sara S Roscioni, Adriana Migliorini, Moritz Gegg, Heiko Lickert. Nat Rev Endocrinol 2016
86
20

A review on insulin trafficking and exocytosis.
Mehrdad Vakilian, Yaser Tahamtani, Kamran Ghaedi. Gene 2019
20
20

Senescence and apoptosis: dueling or complementary cell fates?
Bennett G Childs, Darren J Baker, James L Kirkland, Judith Campisi, Jan M van Deursen. EMBO Rep 2014
327
20

Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice.
Qing Li, Baohui Xu, Sara A Michie, Kathleen H Rubins, Robert D Schreriber, Hugh O McDevitt. Proc Natl Acad Sci U S A 2008
134
20

Patch-Seq Links Single-Cell Transcriptomes to Human Islet Dysfunction in Diabetes.
Joan Camunas-Soler, Xiao-Qing Dai, Yan Hang, Austin Bautista, James Lyon, Kunimasa Suzuki, Seung K Kim, Stephen R Quake, Patrick E MacDonald. Cell Metab 2020
47
20

IRE1α induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress.
Alana G Lerner, John-Paul Upton, P V K Praveen, Rajarshi Ghosh, Yoshimi Nakagawa, Aeid Igbaria, Sarah Shen, Vinh Nguyen, Bradley J Backes, Myriam Heiman,[...]. Cell Metab 2012
483
20

Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor.
Jean-Philippe Coppé, Christopher K Patil, Francis Rodier, Yu Sun, Denise P Muñoz, Joshua Goldstein, Peter S Nelson, Pierre-Yves Desprez, Judith Campisi. PLoS Biol 2008
20

Thioredoxin-interacting protein mediates ER stress-induced β cell death through initiation of the inflammasome.
Christine M Oslowski, Takashi Hara, Bryan O'Sullivan-Murphy, Kohsuke Kanekura, Simin Lu, Mariko Hara, Shinsuke Ishigaki, Lihua J Zhu, Emiko Hayashi, Simon T Hui,[...]. Cell Metab 2012
398
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.